Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, CH | - |
dc.contributor.author | Kim, HK | - |
dc.contributor.author | Lee, SC | - |
dc.contributor.author | Oh, C | - |
dc.contributor.author | Yang, BS | - |
dc.contributor.author | Rhee, HJ | - |
dc.contributor.author | Cho, JH | - |
dc.date.accessioned | 2024-01-21T11:37:34Z | - |
dc.date.available | 2024-01-21T11:37:34Z | - |
dc.date.created | 2022-01-10 | - |
dc.date.issued | 2001-11 | - |
dc.identifier.issn | 0365-6233 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/140063 | - |
dc.description.abstract | In this study, C-2, C-8, N-9 substituted 6-(3-chloroanilino)purine derivatives were synthesized and their inhibitory effects on cyclin-dependent kinases (CDK2, 4) as well as their cytotoxicities were evaluated. The effects of substituents at the C-2, C-8, and N-9 positions of the substituted purine were investigated. Among the compounds tested, [6-(3-chloroanilino)-2-(2-hydroxymethyl-4-hydroxypyrrolidyl)-9-isopropylpurine] (4h) was the most active inhibitor of CDK2 with IC50 of 0.3 muM, i.e. a two-fold increased inhibitory activity as compared to roscovitine. Results from structure-activity relationship studies should allow the design of more potent and selective CDK2 inhibitors, which may provide an effective therapy for cancer or other CDK-dependent diseases. | - |
dc.language | English | - |
dc.publisher | WILEY-V C H VERLAG GMBH | - |
dc.subject | SELECTIVE INHIBITOR | - |
dc.subject | PURINE ANALOGS | - |
dc.subject | CDK INHIBITORS | - |
dc.subject | CDC2 KINASE | - |
dc.subject | ROSCOVITINE | - |
dc.subject | CANCER | - |
dc.subject | POTENT | - |
dc.title | Synthesis and biological properties of C-2, C-8, N-9 substituted 6-(3-chloroanilino)purine derivatives as cyclin-dependent kinase inhibitors. Part II | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/1521-4184(200112)334:11<345::AID-ARDP345>3.0.CO;2-1 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | ARCHIV DER PHARMAZIE, v.334, no.11, pp.345 - 350 | - |
dc.citation.title | ARCHIV DER PHARMAZIE | - |
dc.citation.volume | 334 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 345 | - |
dc.citation.endPage | 350 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000173080100002 | - |
dc.identifier.scopusid | 2-s2.0-0035668305 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | SELECTIVE INHIBITOR | - |
dc.subject.keywordPlus | PURINE ANALOGS | - |
dc.subject.keywordPlus | CDK INHIBITORS | - |
dc.subject.keywordPlus | CDC2 KINASE | - |
dc.subject.keywordPlus | ROSCOVITINE | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | POTENT | - |
dc.subject.keywordAuthor | CDK2 inhibitor | - |
dc.subject.keywordAuthor | m-chloroanilinopurine | - |
dc.subject.keywordAuthor | cell cycle regulation | - |
dc.subject.keywordAuthor | antiproliferative effect | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.